Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
MicroRNAs01:22

MicroRNAs

24.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
MicroRNAs01:22

MicroRNAs

4.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.7K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.7K
Coronary Circulation01:21

Coronary Circulation

7.4K
The heart, an organ critical to survival, gets nourishment not from the blood it pumps but from a separate circulation system known as coronary circulation. This is the shortest circulation in the body and is responsible for supplying the heart with the nutrients it needs to function effectively.
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD133 structural instability as a gateway to medulloblastoma vulnerability.

Cancer cell international·2026
Same author

Metabolomic profile differs between LADA and type 1 diabetes identifying tryptophan metabolism as a pathway involved in the heterogeneity of autoimmune diabetes.

Diabetologia·2026
Same author

Bisphenol A induces a pro-angiogenic-like phenotype via the G protein-coupled receptor 30 (GPR30) pathway.

Scientific reports·2026
Same author

Plasma small RNA profiling reveals a three-miRNA signature associated with early beta cell dysfunction across glucose tolerance stages.

Diabetologia·2026
Same author

Exploration of miR-326 delivery via biocompatible polymeric nanoparticles in medulloblastoma: A preliminary study.

Molecular therapy. Nucleic acids·2026
Same author

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

Communications medicine·2026

Related Experiment Video

Updated: Feb 9, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.0K

Circulating MicroRNAs in Elderly Type 2 Diabetic Patients.

Giuseppina Catanzaro1, Zein Mersini Besharat1, Martina Chiacchiarini2

  • 1Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

International Journal of Endocrinology
|June 1, 2018
PubMed
Summary

Researchers identified circulating microRNAs (miRNAs) to predict type 2 diabetes (T2D) treatment response in elderly patients. Specific miRNAs indicate resistance or positive response to sitagliptin, aiding personalized therapy.

More Related Videos

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Related Experiment Videos

Last Updated: Feb 9, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.0K
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Geriatrics

Background:

  • Circulating microRNAs (miRNAs) role in type 2 diabetes (T2D) in elderly patients remains unclear.
  • Novel biomarkers are needed to monitor T2D treatment efficacy, particularly with sitagliptin.

Purpose of the Study:

  • To identify novel circulating miRNA biomarkers for predicting sitagliptin response in elderly T2D patients.
  • To explore the potential of these miRNAs as noninvasive tools for personalized diabetes management.

Main Methods:

  • Prospective study of 40 elderly T2D patients on metformin.
  • Sitagliptin (DPP-IV inhibitor) added, with follow-up for 15 months.
  • Plasma miRNA profiling at baseline (t0) and 15 months (t15) in responders and nonresponders.

Main Results:

  • Three miRNAs correlated with sitagliptin response: miR-378 (resistance), miR-126-3p and miR-223 (positive response).
  • Patients were classified as responders (HbA1c < 7.5% or reduction > 0.5%) or nonresponders.
  • Distinct miRNA profiles were observed between responder and nonresponder groups.

Conclusions:

  • Circulating miRNAs, including miR-378, miR-126-3p, and miR-223, can predict response to sitagliptin in elderly T2D patients.
  • These miRNAs hold potential for developing noninvasive diagnostic tools to guide therapy and predict complications.
  • Personalized monitoring of T2D treatment response may be enhanced through miRNA analysis.